Pharmaceutical companies are facing uncertainty as Donald Trump’s tariff threats weigh heavily on their stocks. Major pharmaceutical giants like Pfizer and Eli Lilly are grappling with potential price hikes for drugs due to his proposed Most Favored Nation drug pricing for Medicaid. This has triggered a wave of volatility in the industry, with CEOs like David A. Ricks of Eli Lilly working on contingency plans such as bulk shipments from Ireland. The impact of these tariffs extends beyond individual companies, potentially disrupting global supply chains and influencing U.S. financial markets. Experts predict that if tariffs are implemented, they could dampen investments in the sector due to uncertainty over international trade.